Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

Noninvasive Tests for NAFLD: Where Are We Now?

Authors: Alnimer L and Noureddin M
Published in Clinical and Molecular Hepatology (April 2023)
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Read MoreNoninvasive Tests for NAFLD: Where Are We Now?

Costs of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Authors: Tapper EB, Bonafede M, Fishman J, et al.
Published in J Med Econ 2023
The rising healthcare costs of NASH highlight the need for early intervention. Higher FIB-4 scores correlate with increased healthcare expenses. Early-stage intervention can reduce the burden on patients and the healthcare system.
Read MoreCosts of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Non-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A Review

Authors: Lazarus JV, Castera L, Mark HE, et al
Published in JHEP Rep 2022
Heterogeneity in cut-off points for non-invasive fibrosis tests impacts NAFLD risk stratification. Standardized guidelines could improve consistency and accuracy in identifying patients requiring specialist care.
Read MoreNon-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A Review

Physician-Stated vs Clinically-Derived Reference Fibrosis Score in NASH: A Review

Authors: Anstee QM, Hallsworth K, Lynch N, et al
Published in Pragmat Obs Res 2023
Physicians often underestimate or overestimate fibrosis severity in NASH, leading to concerns about appropriate treatment. Standardized interpretations of risk stratification tools are needed.
Read MorePhysician-Stated vs Clinically-Derived Reference Fibrosis Score in NASH: A Review

Non-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: A Review

Authors: Boursier J, Hagström H, Ekstedt M, et al.
Published in J Hepatol 2022
FIB4 and VCTE show promise in predicting prognosis for NAFLD patients. These non-invasive tests offer an alternative to liver biopsies for risk stratification. Quick and easily prescribed, they can streamline referrals and specialized management. A sequential algorithm with FIB4 and VCTE may improve NAFLD care.
Read MoreNon-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: A Review

NAFLD and NASH Occurring After Liver Transplantation: A Review

Authors: Lonardo A, Mantovani A, Petta S, et al.
Published in Nat Rev Endocrinol 2023
Recurrence of NASH/NAFLD after liver transplantation requires attention. Factors include weight gain, post-transplant diabetes, and immunosuppressant drugs. Donor-related genetic risk factors also contribute. A multidisciplinary approach is essential for prevention and management.
Read MoreNAFLD and NASH Occurring After Liver Transplantation: A Review

Surveillance in Patients with Non-cirrhotic NAFLD-related HCC: Obstacles and Solutions

Authors: Shah PA, Patil R, Harrison SA
Published in Hepatology 2023
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease encompassing simple hepatic steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).
Read MoreSurveillance in Patients with Non-cirrhotic NAFLD-related HCC: Obstacles and Solutions

The PPARα-FABP1 Axis: A New Target for NASH Therapies?

Authors: Yan T, Luo Y, Yan N et al.
Published in Hepatology 2023
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Read MoreThe PPARα-FABP1 Axis: A New Target for NASH Therapies?

Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Authors: Purssell H, Whorwell PJ, Athwal VS, et al.
Published in World J Hepatol 2021
Recently, there has been interest in the apparent co-incidence of NAFLD in patients with IBS mainly driven by improved understanding of their shared risk factors and pathophysiology H. Purssell et al. (Manchester University NHS Foundation Trust, UK)......
Read MoreNon-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES